ImmunityBio IBRX
NASDAQ IBRX
$10.28 +1.00 (+10.78%)
At close: Oct 2, 2026 · 4:00 PM EDT

ImmunityBio (IBRX) Cost of Revenue (2025 - 2026)

Updated

ImmunityBio (IBRX) reported Cost of Revenue of $298,000 for Q2 2026, up 119.1% from $136,000 a year earlier and up 25.2% from the prior quarter.

Analysis

ImmunityBio (IBRX) Cost of Revenue (2025 - 2026) Analysis & Trends

Over the twelve months ended Jun 30, 2026, ImmunityBio's Cost of Revenue came in at $1.1 million, up 464.4% year-over-year; for FY2025, it was $753,000.

  • Five-year quarterly Cost of Revenue spans a low of $58,000 in Q1 2025 and a high of $382,000 in Q4 2025.
  • Per Business Quant data, the three quarters before Q2 2026 came in at $238,000 (Q1 2026), $382,000 (Q4 2025) and $177,000 (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cost of Rev (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn 3.27 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn 8.05 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn 4.29 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn 4.40 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn 3.71 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn 2.52 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn 2.81 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn 1.58 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn 4.09 Bn
10 ImmunityBio 10.83 Bn 9.59 Bn 50.94 Mn 298,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 298,000.00
Mar 31, 2026 238,000.00
Dec 31, 2025 382,000.00
Sep 30, 2025 177,000.00
Jun 30, 2025 136,000.00
Mar 31, 2025 58,000.00
API Access

ImmunityBio Cost of Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cost-of-revenue&ticker=IBRX&period=max&api_key=YOUR_API_KEY